Outlook of the humanized mice model market with reference to the healthcare life sciences sector
Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.
A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.
Parent Indicators Healthcare
PMR utilizes a triangulation methodology that is primarily based on overall expenditure on life science research and R&D funding and capital equipment installed base to obtain precise market estimations and insights on life science and biotechnology associated products, technologies, applications and services. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country-specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.
Secondary research is used at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings, equipment installed base in end use facilities, adoption rate and future impact of new technologies. Additionally, per capita consumption of kits, reagents and consumables among end users is tracked at a granular level to obtain the most accurate information. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.
Primary research participants include demand-side respondents such as laboratory managers, procurement managers, research supervisors at academic and research institutes, as well as key opinion leaders in addition to supply-side respondents such as equipment and reagent manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing.
Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project year-on-year growth rates. These Y-o-Y growth projections are checked and aligned as per associated industry/product lifecycles and further utilized to develop market numbers at a holistic level.
On the other hand, we also analyse annual reports of various companies, investor presentations, SEC filings, 10k reports and earning call transcripts operating in the market to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at tier-level based on their revenues, product portfolio and presence.
Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as overall life science research expenditure, R&D funding, industry based demand driving factors impacting the market and its forecast trends apart from other macroeconomic factors.
Standard Report Structure
The global humanized mice model has been segmented into:
Technological improvements in the humanized mice models, include insertion of human genetic material into mice for raising the resemblance with human metabolism and research on more number of human specific infectious agents, which reflects an opportunity for established market players. The production of next-gen humanized mouse models is expected provide exhilarating opportunities to establish robust small animal models for studying the pathogenesis of human-specific transferrable agents as well as testing the efficacy and toxicity of novel experimental vaccines and therapeutic agents.
At a commercial level, the market is witnessing various updates, such as emergence of new techniques for customization, alterations of the host to further reduce innate immunity that hampers human cell engraftment, genetic modifications for providing human-specific growth aspects, and cytokines essential for optimal human cell function and growth. There has been a strengthening relationship between drug discovery and development process and the mice models. As a result, the efforts for extemporizing them is also increasing.
Use of humanized mice models will continue to rise in academic and research institutes
Researchers and academicians worldwide are concentrating on the development of innovative vaccines and therapeutics employing humanized mice model, as the data collected from these models is helpful in predicting the clinical outcome of specific drug in development. This is anticipated to trigger the demand for these models in the pharmaceutical industry, CROs as well as academic and research institutes, thus, benefitting the market in turn. Lately in 2018, a team of Yale researchers has developed a new long-acting and less toxic HIV drug that suppresses HIV virus in humanized mice. A parallel study was conducted by researchers at the Temple University and the University of Pittsburgh for removing HIV DNA from the genomes of humanized mice model.
In July 2017, Pharmatest Services had partnered with Taconic Biosciences in a bid to manufacture a new tentative mouse model with a human immune system, precisely made to research bone metastasis. Scientists of the Center for Infectious Disease Research (CIDR) have also discovered an antibody preventing malaria using a unique humanized mouse liver model.
Adoption of humanized mice models by contract research organizations for clinical research to increase in the coming years
The complete success rate of drugs in the clinical development remains low despite large investments in drug discovery process, predominantly due to inconsistent pre-clinical research. Thereby, humanized mice models are being implemented for bridging the translational gap in the clinical phase. Several research studies have also demonstrated that genetically modified mice are efficient in the documentation of novel gene functions and finding novel drug targets. These models represent influential tools for validating such targets as well as assisting in disease and patient stratification studies. There has been an exponential rise in the employment of mice and other models for translational research and for the in-vivo evaluation of in-vitro selected molecules. Moreover, growing demand for humanized mice model by clinics and laboratories is expected to push the market up in near future.